MX2017012677A - Use of quinoxaline 1,4-di-n-oxide ester derivatives for the treatment of giardiasis as anti-giardia-lamblia agents. - Google Patents

Use of quinoxaline 1,4-di-n-oxide ester derivatives for the treatment of giardiasis as anti-giardia-lamblia agents.

Info

Publication number
MX2017012677A
MX2017012677A MX2017012677A MX2017012677A MX2017012677A MX 2017012677 A MX2017012677 A MX 2017012677A MX 2017012677 A MX2017012677 A MX 2017012677A MX 2017012677 A MX2017012677 A MX 2017012677A MX 2017012677 A MX2017012677 A MX 2017012677A
Authority
MX
Mexico
Prior art keywords
quinoxaline
ester derivatives
giardiasis
oxide ester
lamblia
Prior art date
Application number
MX2017012677A
Other languages
Spanish (es)
Inventor
Rivera Sánchez Gildardo
Elizabeth BARBOSA CABRERA Reyna
Original Assignee
Inst Politecnico Nacional
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Politecnico Nacional filed Critical Inst Politecnico Nacional
Priority to MX2017012677A priority Critical patent/MX2017012677A/en
Publication of MX2017012677A publication Critical patent/MX2017012677A/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure is related to the use of quinoxaline 1,4-di-N-oxide ester derivatives with excellent selectivity on Giardia lamblia. The present invention comprises the quinoxaline 1,4-di-N-oxide ester derivatives, as well as their pharmaceutically acceptable salts and its use in medicines to treat humans and mammalian animals against the disease called giardiasis.
MX2017012677A 2017-10-02 2017-10-02 Use of quinoxaline 1,4-di-n-oxide ester derivatives for the treatment of giardiasis as anti-giardia-lamblia agents. MX2017012677A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2017012677A MX2017012677A (en) 2017-10-02 2017-10-02 Use of quinoxaline 1,4-di-n-oxide ester derivatives for the treatment of giardiasis as anti-giardia-lamblia agents.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2017012677A MX2017012677A (en) 2017-10-02 2017-10-02 Use of quinoxaline 1,4-di-n-oxide ester derivatives for the treatment of giardiasis as anti-giardia-lamblia agents.

Publications (1)

Publication Number Publication Date
MX2017012677A true MX2017012677A (en) 2019-04-03

Family

ID=66823379

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012677A MX2017012677A (en) 2017-10-02 2017-10-02 Use of quinoxaline 1,4-di-n-oxide ester derivatives for the treatment of giardiasis as anti-giardia-lamblia agents.

Country Status (1)

Country Link
MX (1) MX2017012677A (en)

Similar Documents

Publication Publication Date Title
EA201990665A1 (en) HPK1 REGULATORS BASED ON PYRAZOLOPYRIDINE DERIVATIVES AND THEIR APPLICATION FOR TREATMENT OF CANCER
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
MX2020012165A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer.
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MX2017004234A (en) Egfr inhibitor, and preparation and application thereof.
EA201691151A1 (en) CONNECTIONS FOR THE TREATMENT OF PATIENTS WITH ROS1-MUTANT CANCER CELLS
EA201500923A1 (en) SUBSTITUTED (BENZYL CYANOMETHYL) AMIDA 2-AZABICYCLO [2.2.1] HEPTAN-3-CARBON ACIDS AS KATPSIN C INHIBITORS
SA518400356B1 (en) Arginase inhibitors and their therapeutic applications
UY37466A (en) N-HYDROXIAMIDINHETEROCICLES SUBSTITUTED AS MODULATORS OF INDOLAMINE 2,3-DIOXYGENASE
PH12017501095A1 (en) Piperidine derivatives as hdac1/2 inhibitors
MX2017006049A (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahy dropyridines as bace1 inhibitors.
MY199091A (en) Therapeutic compounds
CN107406464A8 (en) Arginase inhibitor and its therapeutical uses
PH12016502353A1 (en) Pharmaceutical composition
PH12021550872A1 (en) Therapeutic compounds
WO2016004404A3 (en) Gls1 inhibitors for treating disease
EA202091020A1 (en) SUBSTITUTED IMIDAZOPYRIDINAMIDES AND THEIR APPLICATION
MX2019001579A (en) Pharmaceutical compositions comprising akt protein kinase inhibitors.
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
MY201535A (en) Therapeutic compounds
PH12020551179A1 (en) Methods for treating mitochondrial disorder
WO2015155680A3 (en) Pyrazole derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors
MX2016016491A (en) O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated an accumulation of misfolded proteins.
MX2017012677A (en) Use of quinoxaline 1,4-di-n-oxide ester derivatives for the treatment of giardiasis as anti-giardia-lamblia agents.
EA201792170A1 (en) INDOLA DERIVATIVES